Go back to the noodls home page
  • About us
  • Coverage
  • Services
Login

Not yet a member?Join now!|Lost password


  • Home


  • News

    • International News

    • Education

    • Environment

    • Health

    • Technology

      • Internet

    • Science

    • Social and Non-Profit

    • Local News

  • Politics 
    and Policy

    • Government and Public Administration

    • Politics

    • Local Administration

    • International Policy

  • Business 
    and Economy

    • Economy

    • Finance

      • Stock Markets

    • Jobs and Labour

    • Company News

    • Industries

      • Aerospace

      • Agriculture

      • Chemicals

        • Plastics and Rubber

      • Consumer Goods

      • Construction

      • Defense

      • Consumer Electronics

      • Energy

        • Nuclear Energy

        • Oil and Gas

        • Renewable and Alternative Energy

      • Financial Service and Investment

        • Banking

        • Insurance

      • Fishing and Aquaculture

      • Information Technology

      • Industrial and Manufacturing

        • Engineering and Heavy Industry

      • Metals

      • Mining

      • Pharmaceuticals

      • Real Estate

      • Services

        • Legal

        • Marketing and Communications

      • Telecommunications

      • Textile

      • Tobacco

      • Trade and Commerce

        • Retail

      • Transportation

        • Air Transportation

        • Maritime Transportation

        • Rail Transportation

        • Road Transportation

      • Utilities

      • Wood Industry

  • Arts 
    and Culture

    • Art

    • Book and Literature

    • Media and Entertainment

      • Cinema

      • Music

      • Radio and Television

    • Media

  • Lifestyle 
    and Leisure

    • Auto and Motors

    • Home and Garden

    • Fashion and Luxury

      • Clothing and Accessories

      • Cosmetics

      • Jewelry and Watches

    • Food and Drink

    • Travel and Tourism

    • Yacht and Sailing


  • Sports

    • Baseball

    • Basketball

    • Boxing

    • Cricket

    • Cycling

    • Football (American)

    • Football (Australian)

    • Football (Soccer)

    • Golf

    • Hockey

    • Rugby

    • Skiing and Winter Sports

    • Tennis

    • Volleyball

Agilent Technologies Inc.

12/04/2012 | Press release

WiCell Teams with Agilent Technologies to Offer High-Resolution CGH+SNP Microarray Service

distributed by noodls on 12/04/2012 11:27

Print Print

Sharing and Personal Tools

Please select the service you want to use:

  • Newsvine
  • Digg
  • Delicious
  • StumbleUpon
  • Technorati
  • Buzz
  • Favorites
  • Google Reader

Please use the above public link if you want to share this noodl on another website

Close

SANTA CLARA, Calif., and MADISON, Wis., Dec. 4, 2012

Agilent Technologies Inc. (NYSE: A) and WiCell, a world leader in the cytogenetic testing of mouse and human embryonic stem cells and induced pluripotent stem cells, today announced that WiCell is now offering comparative genomic hybridization plus single nucleotide polymorphism microarray analysis using the Agilent SurePrint G3 Human Genome CGH+SNP Microarray.

Unlike previous assays that required performing CGH and SNP separately, the CGH+SNP Microarray detects copy number changes by both SNP and CGH, and simultaneously delivers copy-neutral change information such as loss or absence of heterozygosity. The assay maintains the high-resolution quality achieved with CGH-only microarrays, using probes that have been carefully optimized and validated for maximal sensitivity and specificity.

"WiCell's considerable experience and know-how in cytogenetic analysis and their large CGH dataset for embryonic and induced pluripotent stem cells, partners well with Agilent's technology to enable robust detection capabilities vital for research and commercial development," said Kathleen Shelton, senior director of genomics marketing at Agilent.

Anita Bhattacharyya, Ph.D., senior scientist at University of Wisconsin-Madison's Waisman Center, understands firsthand the value of WiCell's CGH+SNP microarray service: "In my Down syndrome research, I needed the ability to rule out loss of heterozygosity in order to publish my research. I was very happy with my interactions with WiCell; their level of expertise and understanding of what I needed was exceptional. Ultimately, through running the SurePrint CGH+SNP microarray, WiCell allowed me to confidently produce the data within a compressed timeline."

Learn more about WiCell's CGH+SNP microarray service at www.wicell.org/cytogenetics.

About WiCell

WiCell, founded in 1999, is recognized as a world leader in the field of human embryonic stem cell and induced pluripotent stem cells. Serving as the host of the U.S. National Stem Cell Bank from 2005-2009, WiCell built extensive expertise in the banking, characterization and cytogenetic testing of human pluripotent stem cells. WiCell opened the Wisconsin International Stem Cell Bank in 2010 and continues to be the world's leading distributor of human pluripotent stem cells. WiCell is a nonprofit organization, an affiliate of the Wisconsin Alumni Research Foundation and a supporting organization to the University of Wisconsin-Madison. Visit www.wicell.org for more information.

About Agilent in Genomics

Agilent Technologies Inc. is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex Target Enrichment Systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex and its same-day sample-to-sequencer workflow is well suited for next-generation desktop sequencers, whereas SureSelect's ability to accurately capture whole exomes and whole methylomes in a single reaction pairs well with high-throughput next-generation sequencing systems. These are just two products arising from Agilent's expertise in synthesizing custom complex mixtures of long oligonucleotide gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive oligonucleotide fluorescent in situ hybridization product line. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanalyzer to measure sample quality, a target enrichment tool to speed next-generation sequencing, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012.www.agilent.com.

# # #

Contact:

Susan Berg
+ 1 408 553 7093
Susan_berg1@agilent.com

Jessica Martin
+ 1 608-577-6625
jmartin@wicell.org


Smartlinks | Agilent Technologies Inc. | Company News | Industrial and Manufacturing | Stocks and Security Markets | Instrument Engineering | Process Industry | Product and Service | Biology | Biotech Industry | Business and Corporate Announcement | New York Stock Exchange (NYSE) | Börse Frankfurt | Manufacturers of Precision and Optical Instruments | Börse Berlin | Börse Düsseldorf | Börse München | Deutsche Börse (XETRA) | Forbes Global 2000 | Large Cap and Index Constituents | Leading Companies

Back

View original format

Copyright ©2006-2013 noodls.com - VAT IT01709820995 | Privacy Policy | Terms of Use | Feedback | Contact us